Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Hurdles in Cancer Immunotherapy Publisher



Sadeghi F1, 2 ; Moghaddam AS3 ; Soleymanjahi S4, 5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
  2. 2. Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Iran
  3. 3. School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  4. 4. Cancer Research Center, Cancer Institute of Iran, Tehran, Iran
  5. 5. Department of Medicine, School of Medicine, Washington University in St. Louis, St. Louis, MO, United States

Source: Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition Published:2020


Abstract

Recent advances in basic immunology have revealed impressive breakthroughs in the field of cancer immunotherapy, inspiring oncologists to translate this knowledge to the treatment of different types of cancers. However, several hurdles limit the efficiency of immunotherapy in increasing the overall survival of patients (Fig. 31.1). These hurdles rank from practical and economic issues such as feasibility and cost-effectiveness of immunotherapy and design of the clinical trials to the several immunological hurdles. In the immunological hurdles, tumor cells possess several mechanisms to evade the immune system response. A combination of factors such as the production of inhibitory cytokines and soluble factors such as the expression of inhibitory markers and conversion of cellular infiltrates into the tolerizing cells contribute to evasion of the immune system. Moreover, some tumor cells acquire apoptosis resistance through different strategies, and some cause the immune system to autoreact to host tissue. All these mechanisms inhibit tumor regression and the effectiveness of immunotherapy. Moreover, immunotherapy-related toxicities have proven to be a major issue in cancer immunotherapies, which required timely and properly management. Therefore, efforts for minimizing the side effects in parallel to maximizing the efficiency of immunotherapies are still warranted. In this chapter, we discuss the potential hurdles that confront cancer immunotherapy and the potential strategies to overcome these challenges and achieve a successful immune response against tumor. © Springer Nature Switzerland AG 2015, 2021. All rights reserved.
Related Docs
View other Related Docs
1. The Current Landscape of Car T-Cell Therapy for Solid Tumors: Mechanisms, Research Progress, Challenges, and Counterstrategies, Frontiers in Immunology (2023)
2. Car-T Cells: Early Successes in Blood Cancer and Challenges in Solid Tumors, Acta Pharmaceutica Sinica B (2021)
3. Car-Modified T-Cell Therapy for Cancer: An Updated Review, Artificial Cells# Nanomedicine and Biotechnology (2016)
4. Production of Car T-Cells by Gmp-Grade Lentiviral Vectors: Latest Advances and Future Prospects, Critical Reviews in Clinical Laboratory Sciences (2019)
5. Solid Tumors Challenges and New Insights of Car T Cell Engineering, Stem Cell Reviews and Reports (2019)
6. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells, Frontiers in Immunology (2018)
7. Tumor Immunology, Clinical Immunology (2022)
8. Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications, Frontiers in Immunology (2017)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (44)
Hamid Reza Mirzaei (18)
Other Related Docs
9. Immunotherapy of Cancers Comes of Age, Expert Review of Clinical Immunology (2017)
10. Prospects for Chimeric Antigen Receptor (Car) Γδ T Cells: A Potential Game Changer for Adoptive T Cell Cancer Immunotherapy, Cancer Letters (2016)
11. Chimeric Antigen Receptor -T Cell Therapy: Applications and Challenges in Treatment of Allergy and Asthma, Biomedicine and Pharmacotherapy (2020)
12. Genetic Modification of Cytokine Signaling to Enhance Efficacy of Car T Cell Therapy in Solid Tumors, Frontiers in Immunology (2021)
13. Immunotherapy a New Hope for Cancer Treatment: A Review, Pakistan Journal of Biological Sciences (2018)
14. Cancer Stem Cell-Targeted Chimeric Antigen Receptor (Car)-T Cell Therapy: Challenges and Prospects, Acta Pharmaceutica Sinica B (2021)
15. Remote Controlling of Car-T Cells and Toxicity Management: Molecular Switches and Next Generation Cars, Translational Oncology (2021)
16. Predictive and Therapeutic Biomarkers in Chimeric Antigen Receptor T-Cell Therapy: A Clinical Perspective, Journal of Cellular Physiology (2019)
17. Biomarkers for Predicting the Outcome of Various Cancer Immunotherapies, Critical Reviews in Oncology/Hematology (2021)
18. Car T Cell Therapy in Solid Tumors; With an Extensive Focus on Obstacles and Strategies to Overcome the Challenges, International Immunopharmacology (2021)
19. Cancer Immunology, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
20. A Metabolic Switch to Memory Car T Cells: Implications for Cancer Treatment, Cancer Letters (2021)
21. Cancer Immunology, Encyclopedia of Infection and Immunity (2022)
22. Cancer Immunology, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
23. The Immunobiology of Myeloid-Derived Suppressor Cells in Cancer, Tumor Biology (2016)
24. Novel Car T Therapy Is a Ray of Hope in the Treatment of Seriously Ill Aml Patients, Stem Cell Research and Therapy (2021)
25. The Promising Role of Monoclonal Antibodies for Gastric Cancer Treatment, Immunotherapy (2019)
26. The Roles of Cd4+ T-Cells in Tumor Immunity, Cancer Immunology: A Translational Medicine Context# Second Edition (2020)
27. Construction and Functional Characterization of a Fully Human Anti-Cd19 Chimeric Antigen Receptor (Hucar)-Expressing Primary Human T Cells, Journal of Cellular Physiology (2019)
28. Resistance to Immunotherapy in Human Malignancies: Mechanisms, Research Progresses, Challenges, and Opportunities, Journal of Cellular Physiology (2022)
29. Antigenic Targets of Car T Cell Therapy. a Retrospective View on Clinical Trials, Experimental Cell Research (2018)
30. Prolonged Persistence of Chimeric Antigen Receptor (Car) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward, Frontiers in Immunology (2020)
31. Chimeric Antigen Receptor T-Cell Therapy for Breast Cancer, Future Oncology (2021)
32. Attribution of Ghrelin to Cancer; Attempts to Unravel an Apparent Controversy, Frontiers in Oncology (2019)
33. Understanding the Tumor Microenvironment for Effective Immunotherapy, Medicinal Research Reviews (2021)
34. T Cell Engineered With a Novel Nanobody-Based Chimeric Antigen Receptor Against Vegfr2 As a Candidate for Tumor Immunotherapy, IUBMB Life (2019)
35. Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
36. Cancer Nanomedicine: Special Focus on Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
37. Biomarkers for Immune Checkpoint Inhibitors, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
38. Chimeric Antigen Receptor (Car) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead, Cells (2021)
39. Tumor Antigens, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
40. Natural Killer Cells and Acute Myeloid Leukemia: Promises and Challenges, Cancer Immunology# Immunotherapy (2022)
41. A Deep Insight Into Crispr/Cas9 Application in Car-T Cell-Based Tumor Immunotherapies, Stem Cell Research and Therapy (2021)
42. Cell Transfer-Based Immunotherapies in Cancer: A Review, IUBMB Life (2020)
43. Therapeutic Roles of Car T Cells in Infectious Diseases: Clinical Lessons Learnt From Cancer, Reviews in Medical Virology (2022)
44. Immunotherapy of Gastric and Esophageal Cancers, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
45. Tumor Antigens, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
46. The Role of Myeloid-Derived Suppressor Cells in Lung Cancer and Targeted Immunotherapies, Expert Review of Anticancer Therapy (2022)
47. Car-Engineered Nk Cells Versus Car T Cells in Treatment of Glioblastoma; Strength and Flaws, Journal of Neuro-Oncology (2025)
48. Resistance Mechanisms to Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Inhibitors, Expert Opinion on Biological Therapy (2021)
49. Car-Nk Cells for Haematological Cancers, Best Practice and Research: Clinical Haematology (2025)
50. A Vhh-Based Anti-Muc1 Chimeric Antigen Receptor for Specific Retargeting of Human Primary T Cells to Muc1-Positive Cancer Cells, Cell Journal (2021)